LSA
PTGX icon

Leonteq Securities AG’s Protagonist Therapeutics PTGX Stock Holding History

Leonteq Securities AG’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-470
Closed -$13K – 1274
2023
Q2 		$13K Hold
470
– – ﹤0.01% 1007
2023
Q1 		$10.8K Hold
470
– – ﹤0.01% 1010
2022
Q4 		$5.13K Hold
470
– – ﹤0.01% 1133
2022
Q3 		$3.96K Hold
470
– – ﹤0.01% 1145
2022
Q2 		$3.72K Hold
470
– – ﹤0.01% 1165
2022
Q1 		$11.1K Hold
470
– – ﹤0.01% 1098
2021
Q4 		$16.1K Buy
+470
New +$14.9K ﹤0.01% 1092

Other funds holding PTGX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Leonteq Securities AG's PTGX Position: Q3 2023 in Review

Leonteq Securities AG sold out of Protagonist Therapeutics (PTGX) in Q3 2023, closing a stake of 470 shares — an estimated $13K sold.

Leonteq Securities AG first reported a position in PTGX in Q4 2021 and held it in 7 quarters. The position peaked at $16.1K in Q4 2021. 144 funds tracked by Wall St. Rank hold PTGX as of Q3 2023.

  • Leonteq Securities AG reported no remaining Protagonist Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Leonteq Securities AG sold 470 Protagonist Therapeutics shares in Q3 2023, an estimated $13K.
  • Leonteq Securities AG first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 7 quarters.
  • Leonteq Securities AG's Protagonist Therapeutics position peaked at $16.1K in Q4 2021.
  • 144 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2023.

Based on Leonteq Securities AG's 13F filing for Q3 2023, filed 11 Mar 2026.